371 related articles for article (PubMed ID: 27879006)
1. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
Nguyen T; Li JX; Thomas BF; Wiley JL; Kenakin TP; Zhang Y
Med Res Rev; 2017 May; 37(3):441-474. PubMed ID: 27879006
[TBL] [Abstract][Full Text] [Related]
2. Translational potential of allosteric modulators targeting the cannabinoid CB
Lu D; Immadi SS; Wu Z; Kendall DA
Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
[TBL] [Abstract][Full Text] [Related]
3. Assessing Allosteric Modulation of CB
Scott CE; Kendall DA
Methods Enzymol; 2017; 593():317-342. PubMed ID: 28750809
[TBL] [Abstract][Full Text] [Related]
4. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
Khurana L; Mackie K; Piomelli D; Kendall DA
Neuropharmacology; 2017 Sep; 124():3-12. PubMed ID: 28527758
[TBL] [Abstract][Full Text] [Related]
5. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model.
Straiker A; Mitjavila J; Yin D; Gibson A; Mackie K
Pharmacol Res; 2015 Sep; 99():370-6. PubMed ID: 26211948
[TBL] [Abstract][Full Text] [Related]
6. CB
Mielnik CA; Lam VM; Ross RA
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110163. PubMed ID: 33152384
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
Manning JJ; Green HM; Glass M; Finlay DB
Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
[TBL] [Abstract][Full Text] [Related]
8. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
[TBL] [Abstract][Full Text] [Related]
9. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
10. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA
Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
[TBL] [Abstract][Full Text] [Related]
11. A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid (CB
Yang L; Zhu X; Finlay DB; Green H; Glass M; Duffull SB
Br J Pharmacol; 2023 Oct; 180(20):2661-2676. PubMed ID: 37277184
[TBL] [Abstract][Full Text] [Related]
12. Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor.
Ross RA
Br J Pharmacol; 2007 Nov; 152(5):565-6. PubMed ID: 17592508
[TBL] [Abstract][Full Text] [Related]
13. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).
German N; Decker AM; Gilmour BP; Gay EA; Wiley JL; Thomas BF; Zhang Y
J Med Chem; 2014 Sep; 57(18):7758-69. PubMed ID: 25162172
[TBL] [Abstract][Full Text] [Related]
14. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
Gado F; Meini S; Bertini S; Digiacomo M; Macchia M; Manera C
Future Med Chem; 2019 Aug; 11(15):2019-2037. PubMed ID: 31517528
[TBL] [Abstract][Full Text] [Related]
15. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
[TBL] [Abstract][Full Text] [Related]
16. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.
Dopart R; Lu D; Lichtman AH; Kendall DA
Drug Metab Rev; 2018 Feb; 50(1):3-13. PubMed ID: 29355030
[TBL] [Abstract][Full Text] [Related]
17. Structure of an allosteric modulator bound to the CB1 cannabinoid receptor.
Shao Z; Yan W; Chapman K; Ramesh K; Ferrell AJ; Yin J; Wang X; Xu Q; Rosenbaum DM
Nat Chem Biol; 2019 Dec; 15(12):1199-1205. PubMed ID: 31659318
[TBL] [Abstract][Full Text] [Related]
18. Multiple Binding Sites Contribute to the Mechanism of Mixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 Receptor.
Saleh N; Hucke O; Kramer G; Schmidt E; Montel F; Lipinski R; Ferger B; Clark T; Hildebrand PW; Tautermann CS
Angew Chem Int Ed Engl; 2018 Mar; 57(10):2580-2585. PubMed ID: 29314474
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulators restore orthosteric agonist binding to mutated CB
Dopart R; Kendall DA
J Pharm Pharmacol; 2020 Jan; 72(1):84-91. PubMed ID: 31722122
[TBL] [Abstract][Full Text] [Related]
20. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
